CD274 and neoplasm: Another study (ChiCTR2000028900) revealed that the number of PD-L1+ CD163+ tumor-infiltrating lymphocytes was significantly lower in a pCR group than in a non-pCR group after treatment with camrelizumab combined with neoadjuvant CRT (p = 0.017) [37].